Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Puma Biotechnology (PBYI) Other Working Capital Changes (2017 - 2025)

Puma Biotechnology (PBYI) has disclosed Other Working Capital Changes for 9 consecutive years, with $718000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Other Working Capital Changes rose 595.17% year-over-year to $718000.0, compared with a TTM value of $325000.0 through Dec 2025, up 139.59%, and an annual FY2025 reading of $325000.0, up 139.59% over the prior year.
  • Other Working Capital Changes was $718000.0 for Q4 2025 at Puma Biotechnology, up from $84000.0 in the prior quarter.
  • Across five years, Other Working Capital Changes topped out at $4.7 million in Q2 2022 and bottomed at -$3.3 million in Q1 2021.
  • Average Other Working Capital Changes over 5 years is -$161250.0, with a median of -$141500.0 recorded in 2023.
  • The sharpest move saw Other Working Capital Changes surged 4420.95% in 2022, then plummeted 8942.86% in 2025.
  • Year by year, Other Working Capital Changes stood at -$620000.0 in 2021, then plummeted by 171.13% to -$1.7 million in 2022, then surged by 91.79% to -$138000.0 in 2023, then dropped by 5.07% to -$145000.0 in 2024, then skyrocketed by 595.17% to $718000.0 in 2025.
  • Business Quant data shows Other Working Capital Changes for PBYI at $718000.0 in Q4 2025, $84000.0 in Q3 2025, and -$1.3 million in Q2 2025.